Chan RW, Chan MC, Wong AC, Karamanska R, Dell A, H. DAS181 Inhibits H5N1 Influenza virus Infection of Human Lung Tissues. Antimicrob Agents Chemother. 2009 Jul 13
DAS181 is a novel therapeutic candidate against influenza virus which functions via the mechanism of removing the virus receptor, sialic acid (Sia) from the adjacent glycan structures. DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models including cell lines, mice and ferrets. Here we demonstrate that DAS181 treatment leads to desialylation of both the alpha2-6-linked and alpha2-3-linked Sia in the ex vivo human lung tissue culture and primary pneumocytes. DAS181 treatment also effectively protects the human lung tissue and pneumocytes against the highly pathogenic avian influenza (HPAI) H5N1 (A/Vietnam/3046/2004). Two doses of DAS181 treatment given at 12 h apart were sufficient to block H5N1 infection in the ex vivo lung tissue culture. These findings support the potential value of DAS181 as a broad-spectrum therapeutic agent against influenza viruses, especially H5N1.
See Also:
Latest articles in those days:
- The evolution, complexity, and diversity of swine influenza viruses in China: A hidden public health threat 1 days ago
- MHC class II proteins mediate sialic acid independent entry of human and avian H2N2 influenza A viruses 1 days ago
- Histopathologic Features and Viral Antigen Distribution of H5N1 Highly Pathogenic Avian Influenza Virus Clade 2.3.4.4b from the 2022–2023 Outbreak in Iowa Wild Birds 1 days ago
- Detection and characterization of H5N1 HPAIV in environmental samples from a dairy farm 2 days ago
- Genomic Characterization of Highly Pathogenic Avian Influenza A H5N1 Virus Newly Emerged in Dairy Cattle 2 days ago
[Go Top] [Close Window]